Morris Birnbaum

​Morris Birnbaum is senior vice president and chief scientific officer for the internal medicine research unit at Pfizer, where he leads the discovery of novel transformative therapies to reduce the prevalence of cardiometabolic dysfunction. He joined Pfizer in 2014 after a nearly 30-year career as a physician scientist. Birnbaum has been an associate professor of cell biology at Harvard Medical School, professor of medicine and cell biology at University of Pennsylvania’s Perelman School of Medicine, and an investigator of the Howard Hughes Medical Institute. At Penn, he was also associate dean for biomedical cores and associate director of the Institute for Diabetes, Obesity, and Metabolism. Birnbaum has published over 200 refereed papers in scientific journals including Cell, Science, and Nature.